MedTrace Logo

Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium

NCT05718934 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2024-02-20

No results posted yet for this study

Summary

The aim of this study is to compare the use of a low dose sugammadex and neostigmine combined to glycopyrrolate to reverse a rocuronium induced moderate neuromuscular blockade.

Conditions

  • Neuromuscular Blockade

Interventions

DRUG

Neostigmine and glycopyrrolate

See arm descriptions

DRUG

Sugammadex

See arm descriptions

Sponsors & Collaborators

  • Ciusss de L'Est de l'Île de Montréal

    lead OTHER

Principal Investigators

  • Philippe PR Richebé, MD PhD · CIUSSS Est de l'île de Montréal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-08
Primary Completion
2023-12-19
Completion
2023-12-19

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05718934 on ClinicalTrials.gov